Overview
Availability
- Associate Professor David Wyld is:
- Available for supervision
Works
Search Professor David Wyld’s works on UQ eSpace
2014
Conference Publication
Assessment of long course chemoradiotherapy (Lccrt) in regards to completion of chemotherapy. The experience of a tertiary referral hospital
Christie, Hayden, Burge, Matthew, Eastgate, Melissa and Wyld, David (2014). Assessment of long course chemoradiotherapy (Lccrt) in regards to completion of chemotherapy. The experience of a tertiary referral hospital. COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress, Melbourne, Australia, 2-4 December, 2014. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12305
2014
Conference Publication
Success with Lutetium-177 DOTATATE therapy in Cushing's syndrome caused by functional pancreatic neuroendocrine tumor (pNET) with ectopic adrenocorticotropic hormone (ACTH) secretion refractory to concomitant everolimus, pasireotide and metyrapone
Chan, B. A., Wyld, D., Burge, M., Cuneo, R., Macfarlane, D. and Lee, K. (2014). Success with Lutetium-177 DOTATATE therapy in Cushing's syndrome caused by functional pancreatic neuroendocrine tumor (pNET) with ectopic adrenocorticotropic hormone (ACTH) secretion refractory to concomitant everolimus, pasireotide and metyrapone. 11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona Spain, 5 - 7 March 2014. Basel, Switzerland: S. Karger AG.
2014
Journal Article
Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis
Beesley, Vanessa L., Green, Adele C., Wyld, David K., O'Rourke, Peter, Wockner, Leesa F., deFazio, Anna, Butow, Phyliss N., Price, Melanie A., Horwood, Keith R., Clavarino, Alexandra M., Australian Ovarian Cancer Study Group, Australian Ovarian Cancer Study - Quality of Life Study Investigators and Webb, Penelope M. (2014). Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis. Gynecologic Oncology, 132 (1), 130-136. doi: 10.1016/j.ygyno.2013.10.004
2014
Conference Publication
Time from diagnosis of rectal adenocarcinoma to commencement of long course chemoradiotherapy (Lccrt) for metropolitan versus rural patients referred to a Queensland tertiary referral hospital
Christie, Hayden, Burge, Matthew, Eastgate, Melissa and Wyld, David (2014). Time from diagnosis of rectal adenocarcinoma to commencement of long course chemoradiotherapy (Lccrt) for metropolitan versus rural patients referred to a Queensland tertiary referral hospital. COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress, Melbourne, Australia, 2-4 December, 2014. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12305
2014
Conference Publication
Locally advanced and metastatic pancreatic cancer: an assessment of the provision of chemotherapy at a tertiary referral hospital
Christie, Hayden, Burge, Matthew, Eastgate, Melissa and Wyld, David (2014). Locally advanced and metastatic pancreatic cancer: an assessment of the provision of chemotherapy at a tertiary referral hospital. COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress, Melbourne, Australia, 2-4 December, 2014. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12305
2014
Conference Publication
Novel succinate dehydrogenase subunit B intronic mutation in an Australian kindred with variable clinical and imaging phenotype necessitating different treatment modalities including 131-I MIBG and 177-Lutetium DOTATATE
Lee, K., Conway, L., Burge, M., Wyld, D. and Macfarlane, D. (2014). Novel succinate dehydrogenase subunit B intronic mutation in an Australian kindred with variable clinical and imaging phenotype necessitating different treatment modalities including 131-I MIBG and 177-Lutetium DOTATATE. 11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 5 - 7 March 2014. Basel, Switzerland: S. Karger AG.
2013
Journal Article
The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates
Kiely, Belinda E., Martin, Andrew J., Tattersall, Martin H. N., Nowak, Anna K., Goldstein, David, Wilcken, Nicholas R. C., Wyld, David K., Abdi, Ehtesham A., Glasgow, Amanda, Beale, Philip J., Jefford, Michael, Glare, Paul A. and Stockler, Martin R. (2013). The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates. Journal of Clinical Oncology, 31 (28), 3565-3572. doi: 10.1200/JCO.2012.44.7821
2013
Journal Article
Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study
Jordan, S., Steer, C., DeFazio, A., Quinn, M., Obermair, A., Friedlander, M., Francis, J., O'Brien, S., Goss, G., Wyld, D. and Webb, P. (2013). Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study. Gynecologic Oncology, 129 (2), 310-317. doi: 10.1016/j.ygyno.2013.02.007
2013
Conference Publication
Pancreatic cancer patient's moderate or high unmet supportive care needs over time and risk factors of future unmet needs
Beesley, Vanessa L., Janda, Monika, Wockner, Leesa F., O'Rourke, Peter, Gooden, Helen, Goldstein, David, Merrett, Neil D., Wyld, David K. and Neale, Rachel E. (2013). Pancreatic cancer patient's moderate or high unmet supportive care needs over time and risk factors of future unmet needs. COSA's 40th Annual Scientific Meeting. Cancer Care Coming of Age, Adelaide Convention Centre, Adelaide, SA Australia, 12-14 November 2013. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing.
2012
Conference Publication
Pulmonary Embolism in Medical Oncology Patients: Symptomatic Versus Incidental
Thaker, D. A., Blazak, J., Wyld, D., Steinke, K., Hughes, B. and Burge, M. (2012). Pulmonary Embolism in Medical Oncology Patients: Symptomatic Versus Incidental. HOBOKEN: WILEY-BLACKWELL.
2012
Journal Article
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial
Neoptolemos, John P., Moore, Malcolm J., Cox, Trevor F., Valle, Juan W., Palmer, Daniel H., McDonald, Alexander C., Carter, Ross, Tebbutt, Niall C., Dervenis, Christos, Smith, David, Glimelius, Bengt, Charnley, Richard M., Lacaine, François, Scarfe, Andrew G., Middleton, Mark R., Anthoney, Alan, Ghaneh, Paula, Halloran, Christopher M., Lerch, Markus M., Oláh, Attila, Rawcliffe, Charlotte L., Verbeke, Caroline S., Campbell, Fiona, Büchler, Markus W., European Study Group for Pancreatic Cancer and Wyld, David (2012). Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA, 308 (2), 147-56. doi: 10.1001/jama.2012.7352
2012
Journal Article
Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2
Kirchhoff, Tomas, Gaudet, Mia M., Antoniou, Antonis C., McGuffog, Lesley, Humphreys, Manjeet K., Dunning, Alison M., Bojesen, Stig E., Nordestgaard, Borge G., Flyger, Henrik, Kang, Daehee, Yoo, Keun-Young, Noh, Dong-Young, Ahn, Sei-Hyun, Dork, Thilo, Schuermann, Peter, Karstens, Johann H., Hillemanns, Peter, Couch, Fergus J., Olson, Janet, Vachon, Celine, Wang, Xianshu, Cox, Angela, Brock, Ian, Elliott, Graeme, Reed, Malcolm W. R., Burwinkel, Barbara, Meindl, Alfons, Brauch, Hiltrud, Hamann, Ute ... Wyld, David (2012). Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. Plos One, 7 (6) e35706, e35706-1-e35706-10. doi: 10.1371/journal.pone.0035706
2012
Conference Publication
Usefulness of medical oncologists' estimates of survival time in people with advanced cancer
Kiely, Belinda E., Martin, Andrew J., Tattersall, Martin H. N., Nowak, Anna K., Goldstein, David, Wilcken, Nicholas, Wyld, David, Beale, Philip James, Jefford, Michael, Glasgow, Amanda L., Abdi, Ehtesham A., Glare, Paul A. and Stockler, Martin R. (2012). Usefulness of medical oncologists' estimates of survival time in people with advanced cancer. 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 1-6 June 2012. Alexandria, VA USA: American Society of Clinical Oncology.
2012
Conference Publication
Safety of bevacizumab used in routine practice in patients with metastatic colorectal cancer
Dzienis, M., Malczewski, A., Goh, J., Hughes, B., Eastgate, M., Wyld, D. and Burge, M. (2012). Safety of bevacizumab used in routine practice in patients with metastatic colorectal cancer. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Program and Abstracts: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting, Brisbane, QLD Australia, 8-10 August 2012. Wiley-Blackwell Publishing.
2012
Journal Article
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
Chirgwin, Jacquie, Sun, Zhuoxin, Smith, Ian, Price, Karen N., Thuerlimann, Beat, Ejlertsen, Bent, Bonnefoi, Herve, Regan, Meredith M., Goldhirsch, Aron, Coates, Alan S., International Breast Cancer Study Group (IBCSG) and Wyld, David (2012). The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Research and Treatment, 131 (1), 295-306. doi: 10.1007/s10549-011-1741-6
2012
Conference Publication
Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k
Shapiro, Jeremy David, Siu, Lillian L., O'Callaghan. Christopher J., Zalcberg, John Raymond, Moore, Malcolm J., Price, Timothy Jay, Doyle, Catherine, Simes, John, Findlay, Brian Peter, Cronk, Michelle F., Shaikh, Asif, Joubert, Warren Lance, Samson, Benoit, Bonaventura, Antonino, Underhill, Craig, Wyld, David, Walters, Ian B., Phillips, Penny, Tu, Dongsheng and Jonker, Derek J. (2012). Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k. 2012 ASCO Annual Meeting, Chicago Il, United States, 01-05 June 2012. Alexandria, VA United States: American Society of Clinical Oncology.
2012
Conference Publication
Treatment of metastatic neuroendocrine tumours with (Lu)-L-177-octreotate: experience at Royal Brisbane and Women's Hospital
Sharma, A., Burge, M., MacFarlane, D., McDade, H., Kemp, S. and Wyld, D. (2012). Treatment of metastatic neuroendocrine tumours with (Lu)-L-177-octreotate: experience at Royal Brisbane and Women's Hospital. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Program and Abstracts: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting , Brisbane, QLD, Australia, 8 – 10 August 2012. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing.
2011
Journal Article
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Pavel, Marianne E., Hainsworth, John D., Baudin, Eric, Peeters, Marc, Hörsch, Dieter, Winkler, Robert E., Klimovsky, Judith, Lebwohl, David, Jehl, Valentine, Wolin, Edward M., Öberg, Kjell, Van Cutsem, Eric, Yao, James C., RADIANT-2 Study Group and Wyld, D. (2011). Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. The Lancet, 378 (9808), 2005-2012. doi: 10.1016/S0140-6736(11)61742-X
2011
Journal Article
Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: A pilot study
Newton, Melissa J ., Hayes, Sandi C., Janda, Monika, Webb, Penelope M., Obermair, Andreas, Eakin, Elizabeth G., Wyld, David, Gordon, Louisa G. and Beesley, Vanessa L. (2011). Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: A pilot study. BMC Cancer, 11 (1) 389, 389-1-389-9. doi: 10.1186/1471-2407-11-389
2011
Journal Article
Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
Regan, Meredith M, Price, Karen N, Giobbie-Hurder, Anita, Thürlimann, Beat, Gelber, Richard D, International Breast Cancer Study Group and BIG 1-98 Collaborative Group, Colosimo, M., Cheuk, R., Kenny, L., McCarthy, N. and Wyld, D. (2011). Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast cancer research : BCR, 13 (3) 209, 209. doi: 10.1186/bcr2837
Supervision
Availability
- Associate Professor David Wyld is:
- Available for supervision
Looking for a supervisor? Read our advice on how to choose a supervisor.
Supervision history
Completed supervision
-
2020
Master Philosophy
Predictors of dosimetry and outcome to peptide receptor radionuclide therapy in metastatic neuroendocrine tumour.
Principal Advisor
Other advisors: Professor David Pattison
-
2021
Doctor Philosophy
Targeting receptor activator of NF-kB pathways in combination immunotherapy
Associate Advisor
Media
Enquiries
For media enquiries about Associate Professor David Wyld's areas of expertise, story ideas and help finding experts, contact our Media team: